Shi VY, Bhutani T, Fonacier L, Deleuran M, et al. Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND). J Am Acad Dermatol 2022 Apr 16. pii: S0190-9622(22)00608.
PMID: 35439608